This white paper will provide an explanation to the perverse mixture of brand-name biologic companies’ anti-competitive market access tactics and inadequate incentives that have cost the U.S. health care system billions of dollars in lost savings.
The Association for Accessible Medicines (AAM) Biosimilars Council found that delayed entry of biosimilars due to patenting has cost the U.S. health care system an astounding $7.6 billion in lost savings since 2015.
Download the Biosimilars Council’s whitepaper, where you will learn about challenges bringing a biosimilar to market, reimbursement and market access, building the biosimilars marketplace and much more
[email protected] shares additional proof points for #biosimilars. Policymakers can keep the momentum going for patients and payers by supporting shared savings and other initiatives that increase access to biosimilars.